What are the contraindications for alprostadil?

Contraindications for Alprostadil

Alprostadil has no absolute contraindications listed in FDA labeling for neonatal use, but for erectile dysfunction treatment, the only absolute contraindication is the inability to establish an emergency plan for managing prolonged erections when prescribing intracavernosal injection therapy for home use. 1, 2

Specific Contraindications by Formulation

Intracavernosal Injection Therapy

• Patients who cannot recognize or respond to priapism warning signs must not be prescribed intracavernosal alprostadil for home use. 1
• Absence of an established emergency plan for prolonged erections is an absolute contraindication to home use of intracavernosal injection. 1
• Intracavernosal injection therapy is contraindicated in any patient with a penile prosthesis, as it may cause device-related complications. 3

Intraurethral Alprostadil

• Alprostadil should not be used in neonates with respiratory distress syndrome (hyaline membrane disease), as it is indicated only for maintaining patent ductus arteriosus in congenital heart defects. 2

Relative Contraindications and Cautions

Bleeding Disorders

• Use alprostadil cautiously in neonates with bleeding tendencies, as it inhibits platelet aggregation. 2
• Vacuum erection devices are contraindicated in patients with bleeding disorders, but this does not apply to alprostadil itself. 4

Cardiovascular Considerations

• While not an absolute contraindication, patients with recent stroke or myocardial infarction require careful consideration, though guidelines note alprostadil has few contraindications or interactions compared to oral therapies. 4
• Monitor arterial pressure intermittently in all neonates receiving alprostadil; if arterial pressure falls significantly, decrease the infusion rate immediately. 2

Anatomical and Functional Limitations

• Patients lacking adequate manual dexterity or eyesight may not be suitable candidates for self-administration of intracavernosal or intraurethral alprostadil. 4
• Patients with pre-existing lower limb varicosities may experience discomfort with intraurethral alprostadil. 4

Critical Safety Requirements (Not Contraindications)

Mandatory Supervision

• The first dose of both intraurethral and intracavernosal alprostadil must be administered under healthcare provider supervision due to risk of syncope (3% incidence) and prolonged erection. 4, 1, 5
• Healthcare providers must be present to determine the minimal effective dose and monitor for complications before any home use. 4, 1

Patient Education Requirements

• Prescribing physicians must educate patients about prolonged erections, establish an urgent treatment plan, and communicate this plan before initiating therapy. 4, 1
• Patients must report any erection lasting ≥4 hours immediately to prevent irreversible corporal fibrosis and permanent erectile dysfunction. 4, 1

Important Clinical Caveats

• The FDA labeling for neonatal alprostadil explicitly states "None" under contraindications, though multiple precautions exist. 2
• Alprostadil is suitable for a wide range of patients owing to few contraindications or interactions compared to oral PDE5 inhibitors. 4
• Unlike oral therapies, alprostadil can be used in patients with vascular disease where PDE5 inhibitors may be contraindicated. 6, 7
• Treatment must not be administered more than once within a 24-hour period. 1